Moderna's Stock Soars Over Fivefold This Year Amid Clinical Milestones
Moderna (NASDAQ: MRNA) has seen its stock rise over 400% this year, with a trailing-12-month gain of more than 500%. Despite recent declines from earlier highs near $176.66 to around $148 per share, the company recently achieved significant progress in oncology with positive phase 3 trial results for its personalized mRNA-based cancer vaccine intismeran autogene tested alongside Merck’s Keytruda. The clinical success of this investigational therapy has improved Moderna's prospects and increased investor confidence. The vaccine showed notable improvements in recurrence-free survival compared to monotherapy, potentially leading to regulatory approval. This milestone also enhances the value of Moderna’s broader mRNA-based cancer pipeline, which includes several other vaccines at various stages of development. Looking ahead, Moderna has secured FDA approval for its flu vaccine mFLUSIVA and is positioned to capture a share of an $8.9 billion market. Analysts estimate intismeran autogene could reach peak annual revenue of $5.6 billion (split 50/50 with Merck). The company’s valuation remains high, but continued clinical progress may drive further stock appreciation.
Topics: cancer vaccine clinical trial results Moderna mRNA technology